Ashfield Capital Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $10.4M | Buy |
77,250
+90
| +0.1% | +$12.9K | 0.87% | 35 |
|
|
2022
Q2 | $11.8M | Sell |
77,160
-537
| -0.7% | -$82.1K | 0.92% | 33 |
|
|
2022
Q1 | $12.6M | Buy |
77,697
+242
| +0.3% | +$35.2K | 0.81% | 35 |
|
|
2021
Q4 | $10.5M | Sell |
77,455
-18,831
| -20% | -$2.22M | 0.67% | 39 |
|
|
2021
Q3 | $10.4M | Sell |
96,286
-1,824
| -2% | -$208K | 0.74% | 39 |
|
|
2021
Q2 | $11.1M | Sell |
98,110
-7
| -0% | -$788 | 0.79% | 37 |
|
|
2021
Q1 | $10.6M | Buy |
98,117
+898
| +0.9% | +$96.1K | 0.84% | 37 |
|
|
2020
Q4 | $10.4M | Buy |
97,219
+2,150
| +2% | +$207K | 0.85% | 33 |
|
|
2020
Q3 | $8.33M | Sell |
95,069
-1,532
| -2% | -$144K | 0.76% | 39 |
|
|
2020
Q2 | $9.48M | Buy |
96,601
+583
| +0.6% | +$51.3K | 0.94% | 32 |
|
|
2020
Q1 | $7.32M | Buy |
96,018
+1,413
| +1% | +$120K | 0.89% | 36 |
|
|
2019
Q4 | $8.38M | Sell |
94,605
-4,023
| -4% | -$334K | 0.83% | 38 |
|
|
2019
Q3 | $7.47M | Sell |
98,628
-4,291
| -4% | -$294K | 0.81% | 40 |
|
|
2019
Q2 | $7.48M | Sell |
102,919
-6,724
| -6% | -$529K | 0.8% | 37 |
|
|
2019
Q1 | $8.84M | Sell |
109,643
-6,899
| -6% | -$564K | 0.97% | 32 |
|
|
2018
Q4 | $10.7M | Sell |
116,542
-247
| -0.2% | -$21.7K | 1.4% | 20 |
|
|
2018
Q3 | $11M | Buy |
116,789
+4,457
| +4% | +$423K | 1.24% | 23 |
|
|
2018
Q2 | $10.4M | Buy |
112,332
+931
| +0.8% | +$90.9K | 1.3% | 18 |
|
|
2018
Q1 | $10.5M | Sell |
111,401
-697
| -0.6% | -$76.6K | 1.37% | 16 |
|
|
2017
Q4 | $10.8M | Sell |
112,098
-840
| -0.7% | -$79.2K | 1.39% | 15 |
|
|
2017
Q3 | $10M | Sell |
112,938
-191
| -0.2% | -$14.5K | 1.34% | 18 |
|
|
2017
Q2 | $8.2M | Sell |
113,129
-1,706
| -1% | -$115K | 1.12% | 27 |
|
|
2017
Q1 | $7.48M | Buy |
114,835
+2,418
| +2% | +$152K | 1.04% | 26 |
|
|
2016
Q4 | $7.04M | Sell |
112,417
-1,295
| -1% | -$79K | 0.69% | 50 |
|
|
2016
Q3 | $7.17M | Sell |
113,712
-110
| -0.1% | -$7.12K | 0.59% | 58 |
|
|
2016
Q2 | $7.05M | Sell |
113,822
-364
| -0.3% | -$22.2K | 0.57% | 57 |
|
|
2016
Q1 | $6.52M | Buy |
114,186
+4,844
| +4% | +$270K | 0.47% | 66 |
|
|
2015
Q4 | $6.48M | Sell |
109,342
-200
| -0.2% | -$11.5K | 0.44% | 64 |
|
|
2015
Q3 | $5.96M | Sell |
109,542
-57
| -0.1% | -$3.71K | 0.38% | 63 |
|
|
2015
Q2 | $7.36M | Sell |
109,599
-712
| -0.6% | -$46.5K | 0.4% | 60 |
|
|
2015
Q1 | $6.46M | Sell |
110,311
-143
| -0.1% | -$8.64K | 0.34% | 65 |
|
|
2014
Q4 | $7.23M | Buy |
110,454
+1,359
| +1% | +$85.7K | 0.35% | 65 |
|
|
2014
Q3 | $6.3M | Buy |
109,095
+434
| +0.4% | +$24.1K | 0.31% | 71 |
|
|
2014
Q2 | $6.13M | Sell |
108,661
-2,835
| -3% | -$149K | 0.29% | 74 |
|
|
2014
Q1 | $5.73M | Sell |
111,496
-1,395
| -1% | -$70.5K | 0.28% | 72 |
|
|
2013
Q4 | $5.96M | Hold |
112,891
| – | – | 0.28% | 72 |
|
|
2013
Q3 | $5.05M | Sell |
112,891
-2,824
| -2% | -$125K | 0.26% | 74 |
|
|
2013
Q2 | $4.78M | Buy |
+115,715
| New | +$5.06M | 0.26% | 76 |
|
Other funds holding ABBV
Ashfield Capital Partners's ABBV Position: Q3 2022 in Review
Ashfield Capital Partners increased its AbbVie (ABBV) stake by 0.12% in Q3 2022, buying an estimated $12.9K and bringing the position to 77,250 shares worth $10.4M. The position accounts for 0.87% of the portfolio, ranked #35.
Ashfield Capital Partners first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $12.6M in Q1 2022. 2,968 funds tracked by Wall St. Rank hold ABBV as of Q3 2022.
- Ashfield Capital Partners held 77,250 shares of AbbVie worth $10.4M as of Q3 2022.
- Ashfield Capital Partners bought 90 AbbVie shares in Q3 2022, an estimated $12.9K.
- AbbVie made up 0.87% of Ashfield Capital Partners's portfolio in Q3 2022, its #35 holding.
- Ashfield Capital Partners first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Ashfield Capital Partners's AbbVie position peaked at $12.6M in Q1 2022.
- 2,968 funds tracked by Wall St. Rank held AbbVie as of Q3 2022.
Based on Ashfield Capital Partners's 13F filing for Q3 2022, filed 10 Nov 2022.